Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC) : Episode 9
Identifying RAI-Refractory Disease: A Key Aspect of DTC Management
Daniel Bowles, MD, leads a discussion on radioactive iodine (RAI) refractory disease, exploring the incidence and resistance levels, and provides recommendations for identifying patient populations who are ineligible for radioiodine treatment.
EP: 1.Differentiated Thyroid Cancer: Examining Key Epidemiological Trends
EP: 2.Exploring Incidence and Histology of Differentiated Thyroid Cancer
EP: 3.Determining Prognosis for Patients with Differentiated Thyroid Cancer
EP: 4.Predisposition for Patients Developing DTC: Age and Gender
EP: 5.The Role of Molecular Diagnostics in Real-World DTC Management
EP: 6.Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies
EP: 7.The Importance of Thyroidectomy in DTC Patient Care
EP: 8.Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression
Now Viewing
EP: 9.Identifying RAI-Refractory Disease: A Key Aspect of DTC Management
EP: 10.SELECT Trial & DECISION Trial Outcomes and Lessons Learned
EP: 11.Determining Which DTC Patients May Benefit from Systemic Therapy
EP: 12.Exploring Real-World Evidence Presented at ATA 2023
EP: 13.Understanding the Impact of COSMIC-311 and Sequencing in DTC
EP: 14.Toxicity Profiles for DTC Guidelines Therapies
EP: 15.Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment
EP: 16.Neoadjuvant Approach in RAI-R-DTC
EP: 17.Phase 2 ATLEP Trial Results
EP: 18.Reflecting on Differentiated Thyroid Cancer: Final Insights
Related Videos
